Health
Sanofi Boosts Preparedness With $600 Million Singapore Plant
This article is for subscribers only.
Sanofi SA added a new plant in Singapore to make vaccines and other medicines, as the French pharmaceutical group seeks to bolster preparedness for emergencies, including potential pandemics.
The facility, named Modulus, came up at investment of S$800 million (nearly $600 million) at Tuas Biomedical Park in the city-state, according to a statement. It can be adapted to manufacture up to four vaccines or biopharmaceuticals at the same time, and will be fully operational in mid-2026 and create 200 skilled jobs in Singapore.